Delcath Systems (DCTH)
(Delayed Data from NSDQ)
$8.70 USD
0.00 (0.00%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $8.72 +0.02 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Delcath Systems, Inc. [DCTH]
Reports for Purchase
Showing records 81 - 100 ( 150 total )
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Healthcare - 1Q 2013: Quarterly Medical Technology Trading & Acquisition Update
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Healthcare - Notes from the Podium: Med Tech Highlights from the 2013 Roth OC Conference
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Key Milestones Approaching; Reducing Estimates Modestly - Maintain Target
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Q4:12 Financial Results - Focusing on EU Reimbursement and ODAC, Lowering PT to $5 - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
German Reimbursement Attained, Expecting Further Expansion; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Revised NDA Filing Positive - Increases Chance of Favorable Review and Leaves Market Opportunity Unchanged in Our Opinion - REITERATE OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
NDA Acceptance Good, but Cutting PT on Slow Ramp in the Face of High Burn
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Q3:12 Financial Results -- Steady Progress in Europe, Lowering Price Target to $9.55, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
CE Mark Doxorubicin CHEMOSAT Opens Up Chinese Market and Partnership Opportunities for Delcath - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
Chemosat Gets CE Mark for Doxo - Paves Way for Commercialization in Asia
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Delcath Systems, Inc.
Industry: Medical - Instruments
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.